Telix Pharmaceuticals is trading at $12.27, up 4.60%, with no clearly reported company-specific catalyst on August 18, 2026.
- Half-year results are scheduled for August 20, 2026, and may be supporting investor attention but do not directly explain today’s move.
- Broader U.S. futures are weaker, making the gain inconsistent with the supplied market-wide risk-off backdrop.
- Pre-market volume and activity details were unavailable.